Insulin-like growth factor-II is produced by, signals to and is an important survival factor for the mature podocyte in man and mouse

Journal of Pathology

Volumn 230, Issue 1, 2013, Pages 95-106

  Hale, L J ^a   Welsh, G I ^a   Perks, C M ^a   Hurcombe, J A ^a   Moore, S ^a   Hers, I ^a   Saleem, M A ^a   Mathieson, P W ^a   Murphy, A J ^b   Jeansson, M ^b   Holly, J M ^a   Hardouin, S N ^c   Coward, R J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Universite Paris Sud   (France)

Author keywords

glomerular endothelial cell; glomerulus; IGF II; mesangial cell; podocyte; survival

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN A; SOMATOMEDIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; EX VIVO STUDY; GLOMERULOPATHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

AGING; ANIMALS; CELL LINE, TRANSFORMED; CELL SURVIVAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KIDNEY GLOMERULUS; MESANGIAL CELLS; MICE; MICE, TRANSGENIC; PODOCYTES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84876138192     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4165     Document Type: Article

References (54)

1. Halbesma N, Kuiken DS, Brantsma AH, et al,. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17: 2582-2590.
2. Perkovic V, Verdon C, Ninomiya T, et al., The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008; 5: e207.
3. Pavenstadt H, Kriz W, Kretzler M,. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
4. Schlondorff D, Banas B,. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009; 20: 1179-1187.
5. Brown EJ, Schlondorff JS, Becker DJ, et al., Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2009.
6. Lavin PJ, Gbadegesin R, Damodaran TV, et al., Therapeutic targets in focal and segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 2008; 17: 386-392.
7. Shkreli M, Sarin KY, Pech MF, et al., Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat Med 2012; 18: 111-119.
8. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al., Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
9. Kim YH, Goyal M, Kurnit D, et al., Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60: 957-968.
10. Floege J, Hackmann B, Kliem V, et al., Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int 1997; 51: 230-243.
11. Matsusaka T, Xin J, Niwa S, et al., Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005; 16: 1013-1023.
12. Wharram BL, Goyal M, Wiggins JE, et al., Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
13. Tejada T, Catanuto P, Ijaz A, et al., Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 2008; 73: 1385-1393.
14. Coward RJ, Welsh GI, Yang J, et al., The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54: 3095-3102.
15. Welsh GI, Hale LJ, Eremina V, et al., Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12: 329-340.
16. Werner H, Weinstein D, Bentov I,. Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 2008; 114: 17-22.
17. Bach LA,. The insulin-like growth factor system in kidney disease and hypertension. Curr Opin Nephrol Hypertens 2012; 21: 86-91.
18. Ward A., Beck-Wiedemann syndrome and Wilms' tumour. Mol Hum Reprod 1997; 3: 157-168.
19. Conti FG, Striker LJ, Elliot SJ, et al., Synthesis and release of insulin-like growth factor I by mesangial cells in culture. Am J Physiol 1988; 255: F1214-1219.
20. Lupia E, Elliot SJ, Lenz O, et al., IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 1999; 48: 1638-1644.
21. Doi T, Striker LJ, Elliot SJ, et al., Insulin-like growth factor-1 is a progression factor for human mesangial cells. Am J Pathol 1989; 134: 395-404.
22. Fujinaka H, Katsuyama K, Yamamoto K, et al., Expression and localization of insulin-like growth factor binding proteins in normal and proteinuric kidney glomeruli. Nephrology (Carlton) 2010; 15: 700-709.
23. Bridgewater DJ, Dionne JM, Butt MJ, et al., The role of the type I insulin-like growth factor receptor (IGF-IR) in glomerular integrity. Growth Horm IGF Res 2008; 18: 26-37.
24. Bridgewater DJ, Ho J, Sauro V, et al., Insulin-like growth factors inhibit podocyte apoptosis through the PI3 kinase pathway. Kidney Int 2005; 67: 1308-1314.
25. Furstenberger G, Senn HJ,. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
26. Harris LK, Westwood M,. Biology and significance of signalling pathways activated by IGF-II. Growth Factors 2012; 30: 1-12.
27. DeChiara TM, Robertson EJ, Efstratiadis A,. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849-859.
28. Saleem MA, O'Hare MJ, Reiser J, et al., A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630-638.
29. Satchell SC, Tasman CH, Singh A, et al., Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 2006; 69: 1633-1640.
30. Sarrab RM, Lennon R, Ni L, et al., Establishment of conditionally immortalized human glomerular mesangial cells in culture, with unique migratory properties. Am J Physiol Renal Physiol 2011.
31. Davies SC, Wass JA, Ross RJ, et al., The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 1991; 130: 469-473.
32. Hunter RW, Hers I,. Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost 2009; 7: 2123-2130.
33. Jeansson M, Gawlik A, Anderson G, et al., Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 2011; 121: 2278-2289.
34. Hardouin SN, Guo R, Romeo PH, et al., Impaired mesenchymal stem cell differentiation and osteoclastogenesis in mice deficient for Igf2-P2 transcripts. Development 2011; 138: 203-213.
35. Norstedt G, Levinovitz A, Moller C, et al., Expression of insulin-like growth factor I (IGF-I) and IGF-II mRNA during hepatic development, proliferation and carcinogenesis in the rat. Carcinogenesis 1988; 9: 209-213.
36. Sheppard MS, Minuk GY, Bhaumick B, et al., Insulin-like growth factors (IGF) in liver disease: differential changes of IGF-I and IGF-II. Clin Invest Med 1987; 10: 49-53.
37. Holly J, Perks C,. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006; 83: 154-160.
38. Worthmann K, Peters I, Kumpers P, et al., Urinary excretion of IGFBP-1 and -3 correlates with disease activity and differentiates focal segmental glomerulosclerosis and minimal change disease. Growth Factors 2010; 28: 129-138.
39. Bridgewater DJ, Matsell DG,. Insulin-like growth factor binding protein-2 modulates podocyte mitogenesis. Pediatr Nephrol 2003; 18: 1109-1115.
40. Parrizas M, Gazit A, Levitzki A, et al., Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997; 138: 1427-1433.
41. Bouallegue A, Vardatsikos G, Srivastava AK,. Role of insulin-like growth factor 1 receptor and c-Src in endothelin-1- and angiotensin II-induced PKB phosphorylation, and hypertrophic and proliferative responses in vascular smooth muscle cells. Can J Physiol Pharmacol 2009; 87: 1009-1018.
42. Kai K, D'Costa S, Sills RC, et al., Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009; 278: 49-55.
43. Li M, Chiu JF, Gagne J, et al., Age-related differences in insulin-like growth factor-1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells. J Cell Physiol 2008; 217: 377-387.
44. LeRoith D, Werner H, Beitner-Johnson D, et al., Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
45. Welsh GI, Saleem MA,. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol 2011; 8: 14-21.
46. Gockerman A, Prevette T, Jones JI, et al., Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology 1995; 136: 4168-4173.
47. Loeser RF,. Growth factor regulation of chondrocyte integrins. Differential effects of insulin-like growth factor 1 and transforming growth factor-β on α1β1 integrin expression and chondrocyte adhesion to type VI collagen. Arthritis Rheum 1997; 40: 270-276.
48. Jones JI, Clemmons DR,. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
49. White YA, Kyle JT, Wood AW,. Targeted gene knockdown in zebrafish reveals distinct intraembryonic functions for insulin-like growth factor II signaling. Endocrinology 2009; 150: 4366-4375.
50. D'Ercole AJ, Stiles AD, Underwood LE,. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984; 81: 935-939.
51. Berggren R, Batuman V,. HIV-associated renal disorders: recent insights into pathogenesis and treatment. Curr HIV/AIDS Rep 2005; 2: 109-115.
52. Kim JJ, Accili D,. Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res 2002; 12: 84-90.
53. Lamberts SW, van den Beld AW, van der Lely AJ,. The endocrinology of aging. Science 1997; 278: 419-424.
54. Eremina V, Cui S, Gerber H, et al., Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735.